The "Global Precision Medicine Market" report has been added to ResearchAndMarkets.com' s offering. The global precision medicine market is expected to have a significant compounded annual growth rate of 9.7% and have a market size in excess of USD 96 Bn by 2023. North America dominates the global market due to the high incidence of cancer and incr
Gainers Arcadia Biosciences, Inc. rose 30.3 percent to $6.49 in pre-market trading after receivings US Patent for extended shelf life wheat trait designed to increase whole grain consumption and minimize waste. XTL Biopharmaceuticals Ltd. rose 29.2 percent to $3.10 in pre-market trading. AcelRx Pharmaceuticals, Inc. shares rose 26.9 percent to $5.0
Gainers XTL Biopharmaceuticals Ltd. climbed 24.6 percent to $2.99. Krystal Biotech, Inc. shares climbed 19.7 percent to $18.77 after the company's Phase 1/ 2 trial of KB103 for dystrophic epidermolysis bullosa met all primary efficacy and safety endpoints. Cambium Learning Group, Inc. climbed 19.3 percent to $14.395 after the company agreed to be a
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation No 596/ 2014. Cambridge, UK and Indianapolis, US- 15 October 2018: Acacia Pharma Group plc provides an update following receipt of a Complete Response Letter from the US Food and Drug Administration in respect of its New Drug Application for B
Analyst Ratings For AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Today, Oppenheimer reiterated its Hold rating on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). There are 4 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock. The current consensus rating on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is Buy with a consensus target
San Francisco, CA 10/15/2018 Global Addiction Treatments Market: Snapshot. The menace of drugs has been dogging our society for decades on end now. On one hand, authorities and police are trying to curtail the problem with an iron hand, on the other hand, healthcare institutes and pharmaceutical companies are pulling out all stops to cure add
Albany, NY 10/15/2018 Advanced drug delivery devices include drug-eluting devices that can be further categorized into biodegradable and non-biodegradable drug delivery systems. Biodegradable drug-eluting devices are used for drug delivery and after implantation these devices decompose over time. They are generally made up of biocompatible...
Advicenne, a specialty pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, announced today that it has received a No Objection Letter to extend its ARENA-2 pivotal Phase III trial for the treatment of distal Renal Tubular Acidosis in Canada from Health Can
Aevi Genomic Medicine, Inc. today announced that it has reached full enrollment of Part B of its Phase 2 ASCEND clinical trial. Part A completed enrollment in August 2018. The accelerated enrollment in Part B will allow the Company to provide complete top line data for both Parts A and B of the ASCEND trial in January 2019. Individual and pooled
Aimmune Therapeutics a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study, with Regeneron and Sanofi, of AR101 with adjunctive dupilumab in peanut-allergic patients. As quoted in the press release:. We are delighted to have Regeneron and Sanofi join u
Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study, with Regeneron and Sanofi, of AR101 with adjunctive dupilumab in peanut-allergic patients. We are delighted to have Regeneron and Sanofi join us in our commitment to imp
Analyst Ratings For Aimmune Therapeutics Inc (NASDAQ:AIMT) Today, Cantor Fitzgerald set its price target on Aimmune Therapeutics Inc (NASDAQ:AIMT) to $62.00 per share. There are 8 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock. The current consensus rating on Aimmune Therapeutics Inc (NASDAQ:AIMT) is Buy with a con
Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that important findings from multiple studies on progressive familial intrahepatic cholestasis and other cholestatic liver diseases will be presented at major upcoming North American liver meetings.
Alnylam Pharmaceuticals, the leading RNAi therapeutics company, today announced that in consultation with the U.S. Food and Drug Administration, the Company plans to pursue a full approval based on the complete results of the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the...
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced that in consultation with the U.S. Food and Drug Administration, the Company plans to pursue a full approval based on the complete results of the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for
WASHINGTON- Alnylam Pharmaceuticals Inc., an RNAi therapeutics company, said that in consultation with the U.S. Food and Drug Administration, it plans to pursue a full approval of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 or ALAS1 for the treatment of acute hepatic porphyria or AHP. Based on our positiv
Anixa Biosciences, Inc., a biotechnology company focused on using the body's immune system to fight cancer, today announced it has filed an IVD pre-submission with the US Food and Drug Administration for use of its Cchek? artificial intelligence based cancer detection technology, as a prostate cancer test. Dr. Kumar continued, "This is a major
Drugmakers to disclose prices for medicines advertised on TV AP-NORC Poll: Many caregivers neglecting their own health UK offers prescription for loneliness, no drugs involved Study: Without Medicaid expansion, poor forgo medical care Marijuana legalization in Canada won't change NHL yet Guards, inmates ally against state in radon-exposure cases...
Applied Therapeutics Inc., a privately held biotechnology company focused on developing transformative drugs in areas of high unmet medical need, announced today that it will present data on AT-007, a novel investigational aldose reductase inhibitor, at the 2018 National Organization for Rare Disorders' Rare Diseases& Orphan Products Breakthrough
Analyst Ratings For Arbutus Biopharma Corp (NASDAQ:ABUS) Today, Arbutus Biopharma Corp (NASDAQ:ABUS) stock received an upgrade by Wedbush from Underperform to Hold with a price target of $5.00. There are 4 Hold Ratings, 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock. The current consensus rating on Arbutus Biopharma Corp (NASDAQ
Analyst Ratings For Arbutus Biopharma Corp (NASDAQ:ABUS) Today, Arbutus Biopharma Corp (NASDAQ:ABUS) stock received an upgrade by Wedbush from Underperform to Neutral with a price target of $5.00. There are 4 Hold Ratings, 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock. The current consensus rating on Arbutus Biopharma Corp (NAS
Arrowhead Pharmaceuticals Inc. today announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-ANG3, an RNAi-based investigational medicine targeting angiopoietin like protein 3 being developed for the treatment of dyslipidemias and metabolic diseases. Chris Anzalone, Ph.D., president and CEO of Arrowhead...
Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that preliminary results of pilot studies in China in which patients received T-cell receptor affinity enhancing specific T-cell therapy showed...
People and animals suffering from the deadliest form of brain cancer are undergoing similar treatment in an NIH- funded clinical trial through the University of Alabama at Birmingham, Auburn Universitys College of Veterinary Medicine and two other currently enrolled Southeastern veterinary programs. Renee Chambers, who holds a doctor of veterinary.
Avadel Pharmaceuticals plc, a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, presented data from two abstracts from Phase 3 clinical trials of NOCTIVA? at the American Urogynecologic Society Annual Scientific Meeting, Pelvic Floor Disorder Week 2018 in Chicago, Illinois fro
